Abstracts tagged "Cardiovascular"

Abstract Number: 1462 • ACR Convergence 2023
Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
Sara garcia Perez¹, Jose-Maria Pego-Reigosa², Irene Altabás González¹, Norman Jiménez³, Victor Del campo Perez⁴, JULIA MARTINEZ BARRIO⁵, Maria Galindo-Izquierdo⁶, Jaime Calvo- Alén⁷, Esther Uriarte Isacelaya⁸, Eva Tomero Muriel⁹, Mercedes Freire González¹⁰, Victor Martinez-Taboada¹¹, Paloma Vela¹², Antonio Fernandez-Nebro¹³, Alejandro Olivé-Marqués¹⁴, Javier Narvaez¹⁵, Raúl Menor-Almagro¹⁶, Gregorio Santos Soler¹⁷, José Ángel Hernández Beriain¹⁸, Javier Manero ruiz¹⁹, Elena Aurrecoechea Aguinaga²⁰, Oihane Ibarguengoitia-Barrena²¹, Carlos Montilla-Morales²², Gema Bonilla²³, Vicente Torrente-Segarra²⁴, Ana Paula Cacheda²⁵, Maria J. García-Villanueva²⁶, Clara Moriano Morales²⁷, Concepción Fito Manteca²⁸, Cristina Bohórquez²⁹, Nuria Lozano Rivas³⁰ and Iñigo Rúa-Figueroa³¹, ¹Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁴Department of Epidemiology, University Hospital of Vigo, IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ⁵Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁶Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ⁹Rheumatology, Hospital La Princesa, Madrid, Spain, ¹⁰Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹¹Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹²Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹³Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁴Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ¹⁷Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ¹⁸Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, ²⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²²Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁴Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²⁵Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ²⁶Hospital Ramón y Cajal, Madrid, Spain, ²⁷Rheumatology, Hospital Universitario de León, León, Spain, ²⁸Department of Rheumatology, University Hospital of Navarra, Pamplona, Spain, ²⁹Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, ³⁰Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…
Abstract Number: 2097 • ACR Convergence 2023
Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque
Natalia Guajardo-Jauregui¹, Iris Colunga², José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Rosa Arvizu-Rivera³ and Jesus Alberto Cardenas-De la Garza⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Cardiovascular disease is the major cause of death in rheumatoid arthritis (RA) patients. Cardiovascular risk algorithms are employed to assess the likelihood of experiencing…
Abstract Number: 2257 • ACR Convergence 2023
Outcomes and Clinical Features of Acute Coronary Syndrome in Patients with SLE: A 14-Year Real-World Study (2006-2019)
Konstantinos Parperis¹ and Bikash Bhattarai², ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Valleywisehealth, Phoenix, AZ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease associated with an increased risk of cardiovascular complications, including acute coronary syndrome (ACS). However, there…
Abstract Number: 0390 • ACR Convergence 2023
Statins Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Elizabeth Hernandez³, Maria Pia Adorni⁴, Francesca Zimetti², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Department of Food and Drug, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Department of Medicine and Surgery, Unit of Neuroscience, University of Parma, Parma, Italy
Background/Purpose: Cholesterol efflux capacity (CEC) is the main antiatherogenic function of high-density lipoprotein (HDL). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol export from arterial macrophages…
Abstract Number: 0579 • ACR Convergence 2023
Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes
Liisa Hopia¹, Anna Laveskog², Dag Leonard³, Andreas Jonsen⁴, Johanna.T Gustafsson², Iva Gunnarsson⁵, Agneta Zickert⁶, Gunnel Nordmark⁷, Anders Bengtsson⁴, Leonid Padyukov⁸, Johanna Sandling³, Ann-Christine Syvänen⁹, Lars Rönnblom³, Magnus Andersson¹ and Elisabet Svenungsson⁶, ¹Department of Clinical Neuroscience, Unit of Neurology, Karolinska Institutet och Karolinska Universitetssjukhuset, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ⁸Karolinska Institutet, Solna, Sweden, ⁹Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden
Background/Purpose: Ischemic stroke is 2-3 times more common in patients with SLE as compared to the general population, and genetic susceptibility in the STAT4 and…
Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Natalie McCormick¹, Chio Yokose², Jie Wei³, Na Lu⁴, Deborah Wexler¹, Mary De Vera⁵, J. Antonio Avina-Zubieta⁴, Yuqing Zhang⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁷Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
Abstract Number: 1270 • ACR Convergence 2023
Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui¹, José Ramón Azpiri-López², Dionicio A. Galarza-Delgado², Iris Colunga², Jesus Alberto Cardenas-De la Garza³ and Rosa Arvizu-Rivera⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico
Background/Purpose: Current EULAR recommendations for cardiovascular risk (CVR) assessment in rheumatoid arthritis (RA) patients indicate that the CVR evaluation should be performed according to national…
Abstract Number: 1466 • ACR Convergence 2023
Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020
Shreena Kamlesh Gandhi¹, Abhiram Challa², Sandhya Shri Kanniyaram³, Arnav Kamat⁴, Tejasri Polana⁵ and Kaleb Michaud⁶, ¹Kansas University School of Medicine, Wichita, KS, ²KU School of Medicine, Wichita, KS, ³John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ⁴NYCH+H/Woodhull, New York, NY, ⁵Jawaharlal Nehru Medical College, Belgaum, Belgaum, India, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…
Abstract Number: 2103 • ACR Convergence 2023
Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Elizabeth Hernandez³, Maria Pia Adorni⁴, Francesca Zimetti², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Department of Food and Drug, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Department of Medicine and Surgery, Unit of Neuroscience, University of Parma, Parma, Italy
Background/Purpose: High-density lipoprotein (HDL) eliminates cholesterol from atherosclerotic lesions, a function known as cholesterol efflux capacity (CEC). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol transfer…
Abstract Number: 2384 • ACR Convergence 2023
Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group
Lisa Rosenberg¹, Larabe Farrukh¹, Simrin Kooner¹, Moiz Ehtesham¹, Sumbal Wajid¹, Ruben Peredo-Wende² and Shannon Murawski¹, ¹Albany Medical Center, Albany, NY, ²Stratton VA Medical Center, Albany, NY
Background/Purpose: Vascular damage from inflammation in ANCA vasculitis leads to a sustained procoagulant state causing accelerated atherosclerosis. A population-based cohort study found that the risk…
Abstract Number: 002 • 2023 Pediatric Rheumatology Symposium
Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression
Coziana Ciurtin¹, Junjie Peng¹, Pierre Donnes¹, Stacy Ardoin², Laura Schanberg³, Laura Lewandowski⁴, George A Robinson¹ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Nationwide Children's Hospital, Columbus, OH, ³Duke University Medical Center, Durham, NC, ⁴NIAMS, NIH, Bethesda, MD
Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is associated with chronic inflammation and increased risk of atherosclerosis. The APPLE trial was a randomised, placebo-controlled trial of…
Abstract Number: 029 • 2023 Pediatric Rheumatology Symposium
Cardiac Magnetic Resonance Imaging in Children with Systemic Lupus Erythematosus and Scleroderma Spectrum Disorders: A Single Center Experience
Meredith Rae, Tam Doan and Eyal Muscal, Baylor College of Medicine, Houston, TX
Background/Purpose: Cardiac disease is a major cause of morbidity and mortality in children with SLE and SSc. Various studies have demonstrated an association between duration…
Abstract Number: L06 • ACR Convergence 2022
Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
Maya H. Buch¹, Deepak L. Bhatt², Christina Charles-Schoeman³, Jon T. Giles⁴, Ted R. Mikuls⁵, Gary Koch⁶, Steven Ytterberg⁷, Edward Nagy⁸, Hyejin Jo⁹, Kenneth Kwok⁹, Carol A. Connell¹⁰, Karim R. Masri¹¹ and Arne Yndestad¹², ¹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Medicine, University of California, Los Angeles, CA, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁵Division of Rheumatology, University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, ⁶Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁸Pfizer Ltd, Tadworth, Surrey, United Kingdom, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc, Oslo, Norway
Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher risk of…
Abstract Number: 0254 • ACR Convergence 2022
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
Katherine Liao¹, Jon Giles², Pamela Rist¹, Robert Glynn¹, Leah Santacroce¹, Paul Ridker¹, Ahmed Tawakol³, Joan Bathon² and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) treatments are known to cause complex changes in lipids, in part by controlling disease activity. While there are robust data on…
Abstract Number: 0626 • ACR Convergence 2022
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
Meena Afroze Shanta¹, Farheen Sultan Shaikh², Bhanupriya Madarampalli³ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University, Spokane, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Proprotein convertase subtilisin/Kexin type-9 (PCSK9) is the most recognized serine protease for its pathological role in cardiovascular diseases, however, its role in inflammatory diseases,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].